Do PPARγ ligands suppress the growth of cholangiocarcinoma or the cholangiohepatitis induced by the tumor?

PPAR Research

Volumn , Issue , 2008, Pages

  Suzuki, Satoru ^a   Hashizume, Kiyoshi ^a  

^a SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; FATTY ACID BINDING PROTEIN; LEPTIN; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SMAD PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; BILE DUCT CARCINOMA; CANCER INHIBITION; CHOLANGIOHEPATITIS; DIABETES CONTROL; DIABETES MELLITUS; DRUG MECHANISM; HEPATITIS; HUMAN; LIVER INJURY; LIVER TOXICITY; NONHUMAN; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TOXIC HEPATITIS;

EID: 48949118209     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/587401     Document Type: Review

References (29)

1. Mudaliar S., Henry R. R., New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers Annual Review of Medicine 2001 52 239 257
2. Suzuki S., Mori J., Yamazaki M., Sato A., Hosoda W., Hashizume K., Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma Internal Medicine 2007 46 20 1723 1728
3. Han C., Demetris A. J., Michalopoulos G. K., Zhan Q., Shelhamer J. H., Wu T., PPAR γ ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p 21 WAF 1 / Cip 1 pathway Hepatology 2003 38 1 167 177
4. Okano H., Shiraki K., Inoue H., The PPARgamma ligand, 15-deoxy-delta 12,14-PGJ2, regulates apoptosis-related protein expression in cholangio cell carcinoma cells International Journal of Molecular Medicine 2003 12 6 867 870
5. Kobuke T., Tazuma S., Hyogo H., Chayama K., A ligand for peroxisome proliferator-activated receptor γ inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma Digestive Diseases and Sciences 2006 51 9 1650 1657
6. Han C., Demetrist A. J., Liu Y., Shelhamer J. H., Wu T., Transforming growth factor- β (TGF- β) activates cytosolic phospholipase A 2 α (cPL A 2 α)-mediated prostaglandin E 2 (PGE) 2 / EP 1 and peroxisome proliferator-activated receptor- γ (PPAR- γ)/Smad signaling pathways in human liver cancer cells: a novel mechanism for subversion of TGF- β -induced mitoinhibition The Journal of Biological Chemistry 2004 279 43 44344 44354
7. Shimizu Y., Demetris A. J., Gollin S. M., Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells International Journal of Cancer 1992 52 2 252 260
8. Auboeuf D., Rieusset J., Fajas L., Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients Diabetes 1997 46 8 1319 1327
9. Combs T. P., Wagner J. A., Berger J., Induction of adipocyte complement-related protein of 30 kilodaltons by PPAR γ agonists: a potential mechanism of insulin sensitization Endocrinology 2002 143 3 998 1007
10. Spiegelman B. M., PPAR- γ: adipogenic regulator and thiazolidinedione receptor Diabetes 1998 47 4 507 514
11. Arner P., The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones Trends in Endocrinology and Metabolism 2003 14 3 137 145
12. Utaisincharoen P., Ubol S., Tangthawornchaikul N., Chaisuriya P., Sirisinha S., Binding of tumour necrosis factor-alpha (TNF- α) to TNF-RI induces caspase(s)-dependent apoptosis in human cholangiocarcinoma cell lines Clinical & Experimental Immunology 1999 116 1 41 47
13. Nzeako U. C., Guicciardi M. E., Yoon J.-H., Bronk S. F., Gores G. J., COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells Hepatology 2002 35 3 552 559
14. Ohira S., Sasaki M., Harada K., Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor- α and stromal-derived factor-1 released in stroma The American Journal of Pathology 2006 168 4 1155 1168
15. Ishimura N., Isomoto H., Bronk S. F., Gores G. J., Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells American Journal of Physiology 2006 290 1 G129 G136
16. Tanimura Y., Kokuryo T., Tsunoda N., Tumor necrosis factor α promotes invasiveness of cholangiocarcinoma cells via its receptor, TNFR2 Cancer Letters 2005 219 2 205 213
17. Yamauchi T., Kamon J., Waki H., The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity Nature Medicine 2001 7 8 941 946
18. Yang W.-S., Jeng C.-Y., Wu T.-J., Synthetic peroxisome proliferator-activated receptor- γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients Diabetes Care 2002 25 2 376 380
19. Rose D. P., Haffner S. M., Baillargeon J., Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women Endocrine Reviews 2007 28 7 763 777
20. De Vos P., Lefebvre A.-M., Miller S. G., Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ The Journal of Clinical Investigation 1996 98 4 1004 1009
21. Vona-Davis L., Rose D. P., Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression Endocrine-Related Cancer 2007 14 2 189 206
22. Way J. M., Harrington W. W., Brown K. K., Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues Endocrinology 2001 142 3 1269 1277
23. Mutoh M., Niho N., Wakabayashi K., Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc -deficient mice Biological Chemistry 2006 387 4 381 385
24. Elchuri S., Naeemuddin M., Sharpe O., Robinson W. H., Huang T.-T., Identification of biomarkers associated with the development of hepatocellular carcinoma in CuZn superoxide dismutase deficient mice Proteomics 2007 7 12 2121 2129
25. Wang G., Gong Y., Anderson J., Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells Hepatology 2005 42 4 871 879
26. Boelsterli U. A., Bedoucha M., Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPAR γ) expression in the liver: insights from models of obesity and type 2 diabetes Biochemical Pharmacology 2002 63 1 1 10
27. Chilcott J., Tappenden P., Jones M. L., Wight J. P., A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus Clinical Therapeutics 2001 23 11 1792 1823
28. Tolman K. G., Fonseca V., Tan M. H., Dalpiaz A., Narrative review: hepatobiliary disease in type 2 diabetes mellitus Annals of Internal Medicine 2004 141 12 946 956
29. May L. D., Lefkowitch J. H., Kram M. T., Rubin D. E., Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy Annals of Internal Medicine 2002 136 6 449 452